Ultragenyx Pharmaceutical/$RARE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Ticker
$RARE
Sector
Primary listing
Employees
1,294
Headquarters
Website
RARE Metrics
BasicAdvanced
$3.2B
-
-$5.52
0.24
-
Price and volume
Market cap
$3.2B
Beta
0.24
52-week high
$50.68
52-week low
$25.81
Average daily volume
1.5M
Financial strength
Current ratio
2.455
Quick ratio
2.097
Long term debt to equity
510.013
Total debt to equity
588.244
Interest coverage (TTM)
-8.47%
Profitability
EBITDA (TTM)
-469.647
Gross margin (TTM)
-27.50%
Net profit margin (TTM)
-87.34%
Operating margin (TTM)
-82.78%
Effective tax rate (TTM)
-0.48%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-21.59%
Return on equity (TTM)
-180.44%
Valuation
Price to revenue (TTM)
5.294
Price to book
21.75
Price to tangible book (TTM)
-40.92
Price to free cash flow (TTM)
-7.303
Free cash flow yield (TTM)
-13.69%
Free cash flow per share (TTM)
-4.583
Growth
Revenue change (TTM)
26.77%
Earnings per share change (TTM)
-23.61%
3-year revenue growth (CAGR)
22.21%
3-year earnings per share growth (CAGR)
-9.03%
10-year earnings per share growth (CAGR)
8.22%
What the Analysts think about RARE
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
Bulls say / Bears say
The FDA issued a complete response letter for UX111, citing manufacturing and facility concerns even though no clinical data issues were raised, delaying approval and sending shares down 5.4% in extended trading (Reuters)
Ultragenyx’s Phase 3 Orbit study of setrusumab failed to meet the interim analysis threshold for early termination, requiring the trial to continue to final analysis and causing a roughly 25% drop in after-hours share price (Investing.com)
RARE shares touched a 52-week low of $29.58, representing a 51% decline from the recent peak, as the stock suffers from broader biotech sector pressures and investor skepticism despite strong revenue growth (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
RARE Financial Performance
Revenues and expenses
RARE Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical (RARE) has a market cap of $3.2B as of November 04, 2025.
What is the P/E ratio for Ultragenyx Pharmaceutical stock?
The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of November 04, 2025.
Does Ultragenyx Pharmaceutical stock pay dividends?
No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Ultragenyx Pharmaceutical dividend payment date?
Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.